Is Veozah Legit? What the FDA's Boxed Warning, Lawsuits, and Patient Complaints Actually Show

"Is it legit" means something different here than it does for a telehealth brand. Veozah isn't a subscription service or a compounding pharmacy you're trusting with your card number — it's a single manufacturer drug, made by Astellas Pharma, that went through the FDA's standard new-drug approval pathway. So there's no Trustpilot star rating or Better Business Bureau file to check the way you would for a telehealth company; that kind of brand-trust audit simply doesn't apply to a drug sold at your regular pharmacy under any prescriber. The real question, the one worth actually answering, is whether the liver warning attached to Veozah is a serious ongoing risk, whether real patients have had bad experiences beyond that warning, and whether the regulatory and legal record around the drug holds up to scrutiny.

Does Veozah actually cause liver damage? What the FDA's boxed warning really says

Veozah was approved in May 2023 without a boxed warning. That detail matters, because it's easy to assume the liver warning was baked in from the start — it wasn't. The FDA added it later, based on real-world use after the drug reached the market, which is exactly the kind of post-approval safety monitoring the system is supposed to do. On September 12, 2024, the FDA issued an initial safety communication after a single, well-documented postmarketing report: a patient developed liver injury roughly 40 days into treatment, with symptoms including fatigue, nausea, itching, yellowed skin and eyes, pale stools, and dark urine, alongside sharply elevated liver enzymes. Her symptoms resolved after she stopped the drug. Then, in the FDA's follow-up drug safety communication, the agency escalated that finding to a full Boxed Warning — its most serious labeling category — in December 2024.

It's worth being precise about what triggered this. The publicly described basis is one detailed case reported through FDA's adverse event reporting system, not a wave of confirmed cases. A Boxed Warning doesn't mean liver injury is common; it means the FDA judged the risk serious enough, even at a rare rate, that every prescriber and patient needs to see it before the first pill. This wasn't a US-only reaction, either — UK regulators separately required Astellas to update its warnings and monitoring guidance in early 2025, which is a useful cross-check that this wasn't one overcautious agency.

What are real patients actually complaining about, beyond the liver warning?

On Drugs.com, Veozah currently averages roughly 7.4 out of 10 across its patient reviews, with a little over half rating the experience positively and less than one in ten rating it negatively — a respectable but not glowing record. The complaints that show up most are mundane by prescription-drug standards: nausea, headache, insomnia, dizziness, and back or tailbone pain. A recurring theme worth knowing about before you start is that some women describe strong initial relief that fades somewhere around three to six months in, with hot flashes gradually creeping back despite continued use — not a universal experience, but common enough in the reviews to flag.

Cost and coverage friction shows up too — reviewers mention high cash prices and insurance denials, which tracks with what a full breakdown of Veozah's real cost confirms separately. What's notably absent from the patient-review pattern is a cluster of people describing confirmed liver injury themselves; the handful of mentions are more along the lines of a reviewer suggesting others get their liver enzymes checked out of caution, not a first-hand account of harm. A direct search for organized Reddit discussion of Veozah didn't surface a large, citable thread pattern in this research pass — if you search r/menopause yourself, weigh a detailed, dated post over a one-line "stay away" comment with no specifics.

Has anyone sued Astellas, or has the FDA sent a warning letter over Veozah?

These are two different questions that are easy to blur together, so it's worth separating them. An FDA warning letter is a formal enforcement notice, usually about a company's marketing claims or manufacturing practices; a boxed warning is a safety-labeling requirement. As of this writing, no FDA warning letter addressed to Astellas over Veozah's marketing or safety communications turns up in FDA's public records or in trade press — the liver-injury action described above was handled through the standard drug-safety-communication and label-update process, not an enforcement letter.

Lawsuits are a separate, more active story. Since the September 2024 FDA safety signal, a number of plaintiff law firms have begun marketing for clients who developed liver problems after taking Veozah, built around a product-liability, failure-to-warn theory — that Astellas knew or should have known about the risk sooner. What hasn't happened, at least as of this research check, is formal consolidation: Veozah doesn't appear on the U.S. Judicial Panel on Multidistrict Litigation's public list of pending MDL dockets, and one of the firms actively soliciting cases described the litigation itself as being in "early stages," noting it wasn't accepting new Veozah cases at that particular moment. Read that combination for what it is: real interest from plaintiff attorneys building potential cases, not a confirmed mass-tort settlement, verdict, or even a consolidated docket yet. That status can shift quickly in mass-tort litigation, so it's worth a fresh check before you weight it heavily in your own decision.

Is Veozah legitimately FDA-approved, and how is that different from a compounded product?

Veozah went through the FDA's standard new-drug application pathway, backed by the SKYLIGHT phase 3 trial program, and it's manufactured as a single finished product by Astellas — the same review and manufacturing-quality bar that applies to any brand-name pharmaceutical you'd get at a retail pharmacy. That's a fundamentally different category from a compounded bioidentical hormone made to order by a 503A pharmacy: compounded products are legal but aren't independently FDA-tested and approved as a finished drug, batch by batch, the way Veozah is. Ironically, the boxed warning is itself a sign the oversight system is working as designed rather than a sign something is being hidden — post-market surveillance caught a real signal after the drug reached a wider population than its trials, and the label was updated accordingly, in public, with a paper trail anyone can read.

What does the liver monitoring actually involve?

Before you fill the first prescription, your clinician should run baseline liver labs — ALT, AST, alkaline phosphatase, and both total and direct bilirubin. Veozah shouldn't be started at all if your ALT, AST, or bilirubin already sits at twice the upper limit of normal or higher. After that, the schedule the FDA tightened in its December 2024 update calls for testing every month for the first three months, then again at months six and nine.

There are also specific stop rules built into the label: your clinician should discontinue Veozah immediately if transaminases climb above five times the upper limit of normal, or above three times the upper limit combined with bilirubin over twice normal. Separately, you should stop the drug and call your provider right away if you notice fatigue, nausea, vomiting, unusual itching, pale stools, yellowing skin or eyes, dark urine, or pain or swelling in the upper right abdomen. None of this is a formality — it's the actual mechanism by which the one documented case resolved once it was caught, and it's designed to catch a problem early rather than let it progress.

Who should not take Veozah?

• Known cirrhosis of any severity, including the mildest classification (Child-Pugh A) — this is a full contraindication, not just a caution
• Severe renal impairment or end-stage renal disease
• Concurrent use of CYP1A2 inhibitor medications — fluvoxamine is the named strong inhibitor that meaningfully raises fezolinetant levels, with mexiletine, cimetidine, and ciprofloxacin also flagged as interacting drugs to disclose to your prescriber
• Active, untreated liver disease or unexplained abnormal liver enzymes at baseline

One nuance worth understanding: the SKYLIGHT trials that supported approval excluded women with active liver disease or elevated liver enzymes at enrollment. That's a standard, responsible trial-design choice, but it also means the drug's real-world use since 2023 has reached a broader population than the controlled trials ever tested — part of why a safety signal could emerge in post-market surveillance rather than showing up in the phase 3 data itself.

How does Veozah's safety record compare with HRT and other hot-flash options?

"No boxed warning" isn't actually the bar most menopause prescriptions clear. Hormone therapy carries its own long-standing boxed warning — covering cardiovascular disease, breast cancer, and probable dementia risk, rooted in the Women's Health Initiative findings — that applies broadly to systemic estrogen products. So the honest framing isn't warning-versus-no-warning; it's which risk profile actually fits your personal and family history. Veozah's liver signal, at least in the one case FDA has described publicly, was monitorable through routine labs and reversible once caught. HRT's risks are different in kind and, in some scenarios, less immediately reversible. Neither is simply "worse" in the abstract — they suit different women.

Older generic non-hormonal options — low-dose gabapentin, oxybutynin, clonidine, and paroxetine (sold as Brisdelle at the FDA-approved dose) — don't carry a liver boxed warning, but they also weren't studied in a phase 3 program built specifically around this indication the way Veozah was through SKYLIGHT. That's a genuine trade-off: a longer real-world track record and a cleaner liver-safety profile against a less rigorous, purpose-built evidence base for treating hot flashes specifically.

What to actually check before you start

• Confirm your clinician actually orders baseline liver labs before your first fill — this isn't optional per the label, and skipping it removes the main safeguard behind the drug's safety data
• Get the monitoring schedule in writing or set your own reminders — monthly for three months, then at six and nine months — rather than counting on a busy practice to track it for you
• List every medication and supplement you take when you're prescribed Veozah, specifically flagging fluvoxamine or other CYP1A2 inhibitors, since that combination is contraindicated, not just cautioned against
• Know the stop-symptoms by name — fatigue, nausea, itching, pale stools, jaundice, dark urine, right-upper abdominal pain — and treat any of them as a same-day call to your prescriber, not a wait-and-see
• Read a mass-tort law firm's marketing page for what it is: evidence that attorneys are building potential cases, not a finding of guilt, a settlement, or proof the drug caused your specific symptoms

Put together, the record is coherent rather than alarming. Veozah cleared the FDA's standard approval pathway, its boxed warning reflects real post-market surveillance catching a genuine — if so far singularly documented and reversible — signal, and the monitoring schedule attached to it is specific and actionable rather than a vague disclaimer. No FDA warning letter has been issued against Astellas over the drug, and no lawsuit has been consolidated into a formal MDL or produced a settlement or verdict as of this writing, whatever a plaintiff-attorney ad might imply. The honest complaints that do exist center on ordinary side effects, waning effectiveness for some women over time, and the very real sting of its cash price — not fraud, not a hidden safety cover-up, and not a drug quietly failing regulatory scrutiny.